NCT04197310 - Cabozantinib and Nivolumab for Carcinoid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 26, 2019

Primary Completion Date

December 27, 2023

Study Completion Date

January 31, 2024

Conditions

Carcinoid TumorCarcinoid Tumor of GI SystemNeuroendocrine Tumors

Interventions

DRUG

Nivolumab

240mg, intravenously, Day 1 and 15 of a 28 day cycle

DRUG

Cabozantinib

40mg, orally, Daily for a 28 day cycle

Trial Locations (2)

Boston Medical Center, Boston

Dana Farber Cancer Institute, Boston